"First Implantable Continuous Glucose Monitor Receives FDA Approval For Type 1 and Type 2 Diabetes" - Shari Roan
The U.S. Food and Drug Administration has approved the first implantable continuous glucose monitoring (CGM) device for people with type 1 and type 2 diabetes. The device, called the Eversense Continuous Glucose Monitoring System, provides monitoring for up to three months, and it’s approved for people age 18 and older. It’s important for people with diabetes to have choices in how they manage the disease, said Carol Levy, MD, CDE, associate professor of endocrinology, diabetes and bone disease and director of the Mount Sinai Diabetes Center at the Icahn School of Medicine at Mount Sinai, who was an investigator on a key clinical trial of the Eversense device. “This isn’t a one-size-fits-all disease,” she said. “We need to have options to meet each and every one of our patient’s needs. I think this provides a new option for a subset of people with diabetes.”
- Carol Levy, MD, CDE, Associate Professor, Endocrinology, Diabetes and Bone Disease, Obstetrics, Gynecology and Reproductive Science, Director, Mount Sinai Diabetes Center, T1 Diabetes Clinical Research, Icahn School of Medicine at Mount Sinai